An interventional study of Phototherapy and ursodeoxycholic acid (UDCA) in Hyperbilirubinemia, Neonatal Indirect, sponsored by Tishreen University Hospital. Recruiting at 1 site in Syria. Open to participants aged Up to 1 Month. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Tishreen University Hospital · Not applicable, Interventional, and Treatment
This is a prospective, open-label, randomized controlled trial conducted at Lattakia University Hospital (Tishreen University), aiming to evaluate the efficacy of Ursodeoxycholic Acid (UDCA) as an adjuvant to triple phototherapy in the management of indirect hyperbilirubinemia in neonates ≥34 weeks of gestation.
Eligible neonates will be randomly assigned to one of two groups:
Group A: continuous triple phototherapy only
Group B: UDCA (10 mg/kg/day in two oral doses) in addition to triple continuous phototherapy.
Stratified randomization will be applied according to etiology (hemolytic, non-hemolytic, G6PD deficiency). The primary outcome is the rate and time of decline in total and indirect serum bilirubin to below phototherapy thresholds, monitored every 12 hours until discharge.
This trial seeks to determine whether UDCA may reduce phototherapy duration or enhance bilirubin clearance in a safe and effective manner.
Although this is an open-label trial for care providers and participants , the statstican conducting data analysis will be blinded to group allocation to reduce assessment bias.
This is a prospective, open-label, randomized controlled clinical trial designed to assess the efficacy of ursodeoxycholic acid (UDCA) as an adjuvant to continuous triple phototherapy in neonates with indirect hyperbilirubinemia.
The study includes neonates ≥34 weeks gestational age and appropriate for gestational age (AGA), who meet the American Academy of Pediatrics (AAP) criteria for starting phototherapy.
Participants will be randomized 1:1 into two parallel arms:
Group A (Control): Continuous triple phototherapy
Group B (Intervention): Continuous triple phototherapy + oral UDCA at a dose of 10 mg/kg/day divided into two doses, using locally available Ursorasha (Rasha Pharma, license #1991/1192).
Randomization will be performed using stratified block randomization, with three stratification layers to balance known confounding factors across groups:
Total serum bilirubin (TSB) will be monitored every 12 hours and compared across groups. Primary outcome is the time needed for bilirubin to drop below phototherapy threshold, according to age-specific AAP phototherapy nomograms.
Additional secondary analyses will include the rate of bilirubin decline at 24 and 48 hours, need for rescue therapy, and subgroup analysis based on gestational age (late preterm vs term), and jaundice type.
Based on retrospective hospital data, the anticipated enrollment is 70 neonates. However, due to the lower prevalence of G6PD deficiency, this subgroup may not yield enough cases for statistically powered subgroup analysis. It will instead be analyzed descriptively or as exploratory.
The study includes clearly defined inclusion/exclusion criteria and a unified therapeutic protocol applied to all infants.
Inclusion criteria: Neonates ≥34 weeks GA, AGA, with indirect hyperbilirubinemia requiring phototherapy.
Exclusion criteria: Neonates \<34 weeks, non-AGA, suspected/confirmed sepsis, TPN, liver disorders, or infants of diabetic mothers.
This protocol was initiated and registered within 21 days of enrolling the first patient. The study has received initial approval from the Department of Pediatrics at Lattakia University Hospital (formerly Tishreen University Hospital) under Committee Decision #70. Final administrative ethics approval from the university is in progress due to procedural delays in our country.
96 studies on the registry are indexed under Hyperbilirubinemia, Neonatal; 20 are open to participants now.
This study's planned enrollment of 70 is below the median of 100 across 61 interventional studies indexed under Hyperbilirubinemia, Neonatal.
Browse Hyperbilirubinemia, Neonatal studies →Tishreen University Hospital is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Infants who have indirect hyperbilirubinemia recieve continuous triple phototherapy only .
Procedure: Phototherapy
Phototherapy + UDCA
Procedure: Phototherapy · Drug: ursodeoxycholic acid (UDCA)
Triple continuous phototherapy per AAP Guudelines
Also known as: Triple continuous phototherapy
10mg/kg/day orally divided in two doses (URSORASHA) . Given with feeds untill the bilirubin level drop down to limits that don't need therapy due to AAP guidelines.
Also known as: Ursodiol, UDCA
Reduction of total serum bilirubin to below phototherapy threshold
Measurement of serum total bilirubin levels every 12 hours until they fall below the phototherapy threshold based on gestational age and postnatal age. Outcome is considered achieved once bilirubin levels drop below threshold and phototherapy can be discontinued .
Time frame: Day 0 to Day 7
Time to bilirubin reduction below treatment threshold
Time (in hours) from treatment initiation to TSB falling below phototherapy threshold in each group.
Time frame: Day 0 to Day 7
Mean reduction in total serum bilirubin at 12 hours
To compare the average decrease in total serum bilirubin after 12 hours between the two groups.
Time frame: 12 hours of starting therapy
Comparison of Hospital stay between both groups
The total length of hospital stay (in days) will be compared between both groups (phototherapy alone and UDCA + phototherapy) to assess the impac5 of UDCA on hospital stay duration.
Time frame: Day 0 to Day 7
Comparison of bilirubin reduction between late preterm (34weeks-36weeks+6 days) and term infants (≥37 weeks) in each treatment group.
This outcome aims to evaluate whether the gestational maturity of neonates affects the response to the assigned treatment. The kinetics of bilirubin reduction (mg/dL over time) will be analyzed separately within the phototherapy-only group and the phototherapy + UDCA group, comparing late preterm and term neonates.
Time frame: Up to 7 Days
Comparison of bilirubin decline in each gestational age group (preterm vs preterm) and (term vs term) across jaundice types between treatment arms.
This outcome investigates whether the effectiveness of UDCA as an adjuvant varies by both gestational age and jaundice type. Within each gestational age group (late preterm and term), the bilirubin decline trends in rate (mg/dl) will be compared between the treatment groups across each of the following etiologies: * Hemolytic jaundice * Non-hemolytic jaundice * G6PD-related jaundice
Time frame: Day 0 to Day 7.
Need for retreatment
percentage of infants who required re-initiation of phototherapy after initial discontinuation in each Arm .
Time frame: Day 0 to Day 10 , Up to 3 days after treatment discontinuation.
Incidence of adverse effects in the UDCA group
Any reported side effects in neonates receiving UDCA
Time frame: Day 0 to Day 7
Time to bilirubin reduction below threshold between treatment groups within each gestational age category
Time from initiation of treatment to bilirubin falling below treatment threshold for: * Late preterm (34-36+6 weeks): Group A vs. Group B * Term (≥37 weeks): Group A vs. Group B
Time frame: Up to 7 Days
Time to bilirubin reduction between late preterm and term neonates within each treatment group
To assess whether gestational age affects time to bilirubin normalization within each group.
Time frame: Up to 7 Days
Time to bilirubin normalization in each gestational age group across jaundice types
For each gestational age (late preterm, term), compare time to normalization among jaundice types (hemolytic, non-hemolytic, G6PD) between groups.
Time frame: Up to 7 Days.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ursodeoxycholic Acid
Hyperbilirubinemia, Neonatal →
Tishreen University Hospital